StockData
NervGen Pharma Corp. logo

NervGen Pharma Corp. (NGEN) stock

NGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 40-F on Mar 31, 2026Score 5/30
$1.82−0.06 (-3.19%)

Close on Nov 16, 2026Market cap $144.96MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025

Valuation

Market cap
C$206.66M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

EPS, diluted
-0.61 CAD

Trading

Previous close
$1.88
Open
$1.85
Day's range
$1.75 – $2.08
Volume
1,622,545
Average volume (20 days)
655,913
RSI (14 days)
64.1
Volatility (1 year)
85.7%
Relative volume
2.85×

Market cap history

Month-end market cap since 2024, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodNGENS&P 500DifferenceNGEN per yearS&P 500 per year
1 month+14.5%-3.1%+17.5 pts
3 months+4.9%-4.5%+9.3 pts
Year to date-67.5%+9.4%−76.9 pts
1 year-22.9%+11.3%−34.2 pts
3 years+30.9%+70.4%−39.5 pts+9.4%+19.4%
5 years-22.7%+68.6%−91.3 pts-5.0%+11.0%
10 years+18100.0%+297.7%+17802.3 pts+68.3%+14.8%

Three years at a glance

Fiscal years 2023 to 2025, CAD

EPS, diluted

-0.61 CAD
Reported period

Press releases

Releases NervGen Pharma filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About NervGen Pharma

Pharmaceutical Preparations

NervGen Pharma Corp. is a pharmaceutical company based in Canada that engages in scientific research and experimental development. The company focuses its operational efforts on preclinical development, clinical and regulatory activities, chemistry manufacturing and controls, and the licensing and protection of patents. Operating as a development-stage enterprise within the pharmaceutical preparations industry, the business does not report distinct commercial operating segments or commercial product sales to external customers. Its core activities center on proprietary research, development initiatives, and related advisory work directed by executive leadership and medical advisors.

Company profile, executives and history

NervGen Pharma stock: common questions

What is NervGen Pharma's stock price?

NGEN closed at $1.82 on Nov 16, 2026, down 3.19% on the day.

What is NervGen Pharma's market cap?

NervGen Pharma was worth $144.96M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is NGEN's P/E ratio?

NervGen Pharma lost money over fiscal 2025 (diluted EPS -0.61 CAD), so it has no meaningful P/E ratio.

Does NervGen Pharma pay a dividend?

No. NervGen Pharma has not paid a cash dividend over the last twelve months.

How has NGEN stock performed over the past year?

Including dividends, NGEN returned -22.9% over the past year, against +11.3% for the S&P 500.

Who are NervGen Pharma's competitors?

Companies most similar to NervGen Pharma by business, industry and size include HELP, DRUG, MSLE, CMND, MTRI.

See a number that looks wrong?